Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer Care: Visiting ProfessorshipEducation Oncology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative StrategiesRelease Date:Quality Improvement Oncology All Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology PracticeRelease Date:Education Oncology USA Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Biochemical and Molecular Characterization of Marstacimab and TFPI PathwaysRelease Date:Research Rare Disease Brazil, China, Germany, Italy, Japan, Korea, Netherlands, Saudi Arabia, Spain, Turkey, USA, United Kingdom Optimizing RSV diagnosis by improving RSV detection in patients admitted to ED/hospitalized due to respiratory symptomsRelease Date:Quality Improvement Vaccines Austria, Belgium, Bulgaria, Czech Republic, Finland, Greece, Ireland, Israel, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Sweden, Switzerland Title Grant Type Focus Area Country Application Due Date Clinical Data Updates & Treatment Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer(NSCLC)Release Date:Education Oncology USA BOOST - Multiple Myeloma An Oncology Boosting ProgramRelease Date:Quality Improvement Oncology Netherlands PARP-Inhibitor Combination Treatments: Safety and Efficacy in a rapidly changing mCRPC landscapeRelease Date:Education Oncology All Education in the Era of Emerging Hemophilia TherapyRelease Date:Partner: National Bleeding Disorders FoundationEducation Rare Disease Guam, Puerto Rico, USA Education for Patients and Caregivers Living with Bladder Cancer from NMIBC to la/mUCRelease Date:Education Oncology USA USP <797> Pharmaceutical Compounding-Sterile Preparations: Ensuring Compliance Now and For the FutureRelease Date:Education Hospital USA COVID-19 Burden and Benefit of Vaccination - Global excluding US, Canada and TaiwanRelease Date:Education Vaccines All Menopause Hormone Therapy: Evidence-Based Recommendations and PracticesRelease Date:Education Internal Medicine USA Global Call for Collaborators – Pfizer Migraine ResearchRelease Date:Research Internal Medicine All Improving care in headache medicine and the management of migraineRelease Date:Quality Improvement Internal Medicine Israel The Value of axitinib in combination with Immuno-oncology (IO) in Patients with Metastatic Renal Cell Carcinoma (mRCC)Release Date:Research Oncology China Elevating IBD Management Standards Through Targeted EducationRelease Date:Education Inflammation & Immunology Turkey